Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer

Oncology (Williston Park). 2020 May 13;34(5):176-182.

Abstract

Triple-negative breast cancer (TNBC), which accounts for approximately 10% to 15% of breast cancers, remains the most aggressive subtype and is characterized by early disease relapse for a subset of patients. TNBC remains a clinical challenge, given the lack of effective targeted treatments such as endocrine therapy for hormone receptor-positive (HR+) tumors or therapies against HER2.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Immunotherapy
  • Neoadjuvant Therapy
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Treatment Outcome
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / genetics
  • Triple Negative Breast Neoplasms / metabolism
  • Triple Negative Breast Neoplasms / pathology

Substances

  • Biomarkers, Tumor
  • Poly(ADP-ribose) Polymerase Inhibitors